This company listing is no longer active
Radius Health Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Wichtige Informationen
53.5%
Wachstumsrate der Gewinne
50.4%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 24.2% |
| Wachstumsrate der Einnahmen | 10.1% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | n/a |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Radius Recycling: An Attractive, But Volatile, Play On A Cleaner Future
Jun 03Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtype
Aug 11Reevaluating Radius Health
Feb 24Radius Health EPS misses by $0.02, misses on revenue
May 07When Will Radius Health, Inc. (NASDAQ:RDUS) Become Profitable?
Feb 23
Revisiting Radius Health
Feb 01Radius Health acquires global rights to RAD011 in Prader-Willi syndrome
Jan 06How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?
Jan 01
Radius Health on-track for record quarterly revenue for TYMLOS-SC
Dec 15Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2024 | 300 | 36 | N/A | N/A | 5 |
| 12/31/2023 | 272 | 12 | N/A | N/A | 6 |
| 12/31/2022 | 232 | -10 | N/A | N/A | 3 |
| 6/30/2022 | 223 | -69 | -28 | -28 | N/A |
| 3/31/2022 | 217 | -73 | -44 | -44 | N/A |
| 12/31/2021 | 230 | -70 | -22 | -22 | N/A |
| 9/30/2021 | 228 | -76 | -52 | -52 | N/A |
| 6/30/2021 | 249 | -60 | -62 | -62 | N/A |
| 3/31/2021 | 247 | -87 | -60 | -60 | N/A |
| 12/31/2020 | 239 | -109 | -74 | -74 | N/A |
| 9/30/2020 | 232 | -113 | -54 | -54 | N/A |
| 6/30/2020 | 200 | -136 | -75 | -75 | N/A |
| 3/31/2020 | 191 | -128 | -81 | -81 | N/A |
| 12/31/2019 | 173 | -133 | -82 | -82 | N/A |
| 9/30/2019 | 152 | -149 | -115 | -115 | N/A |
| 6/30/2019 | 133 | -169 | -137 | -137 | N/A |
| 3/31/2019 | 115 | -203 | -169 | -169 | N/A |
| 12/31/2018 | 99 | -221 | -205 | -205 | N/A |
| 9/30/2018 | 72 | -251 | -204 | -204 | N/A |
| 6/30/2018 | 58 | -259 | -217 | -215 | N/A |
| 3/31/2018 | 37 | -259 | -235 | -224 | N/A |
| 12/31/2017 | 22 | -254 | -218 | -207 | N/A |
| 9/30/2017 | 14 | -236 | -216 | -204 | N/A |
| 6/30/2017 | 1 | -224 | -192 | -180 | N/A |
| 3/31/2017 | N/A | -199 | -162 | -159 | N/A |
| 12/31/2016 | N/A | -183 | -143 | -140 | N/A |
| 9/30/2016 | N/A | -163 | -133 | -130 | N/A |
| 6/30/2016 | N/A | -145 | -123 | -121 | N/A |
| 3/31/2016 | N/A | -125 | N/A | -101 | N/A |
| 12/31/2015 | N/A | -102 | N/A | -87 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: RDUS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Ertrag vs. Markt: RDUS is forecast to become profitable over the next 3 years, which is considered above average market growth.
Hohe Wachstumserträge: RDUS is expected to become profitable in the next 3 years.
Einnahmen vs. Markt: RDUS's revenue (10.1% per year) is forecast to grow faster than the US market (8% per year).
Hohe Wachstumseinnahmen: RDUS's revenue (10.1% per year) is forecast to grow slower than 20% per year.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Insufficient data to determine if RDUS's Return on Equity is forecast to be high in 3 years time